Drug General Information (ID: DDIN2SUW5Y)
Drug Name			Ranolazine		Drug Info		Fostemsavir		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Analgesics				Antiviral Agents
Structure

Mechanism of Ranolazine-Fostemsavir Interaction (Severity Level: Moderate)
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Ranolazine				Fostemsavir
Mechanism		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 1
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Ranolazine and Fostemsavir

Recommended Action
Management		Caution is recommended if ranolazine is used in combination with other drugs that can prolong the QT interval. Since the magnitude of QTc prolongation increases with increasing plasma concentrations of ranolazine, the maximum recommended dosage of 1000 mg twice daily should not be exceeded. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope. Ranolazine is contraindicated in patients with liver cirrhosis because of the profound effect on QT prolongation in this population.

References
1	European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine.".
2	Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.